CHICAGO, ILLINOIS, February 12, 2019 — XMS Capital Partners, LLC (“XMS”), a global, independent financial services firm focused on providing M&A, corporate advisory and asset management services, announced that it served as exclusive financial advisor to Edwards Lifesciences Corporation (NYSE:EW) on its announced acquisition of CAS Medical Systems, Inc. (NASDAQ:CASM) (CASMED) in an all-cash transaction for $2.45 per share of Common Stock, or an equity value of approximately $100 million.
Edwards, based in Irvine, CA, is the global leader in patient-focused innovations for structural heart disease and critical care monitoring.
CASMED, based in Branford, CT, is a medical technology company dedicated to non-invasive monitoring of tissue oxygenation in the brain.
Frank Oelerich, Managing Director of XMS Capital commented, “It was a privilege for XMS to work with the Edwards team on this important acquisition. CASMED’s sensor capabilities fit well with Edwards’ monitoring platform and the combination will provide better information for physicians and strengthen Edwards’ leading position in critical care monitoring.”
The closing of the transaction is expected to occur during the second quarter of 2019 and is subject to customary closing conditions and regulatory approvals.
About XMS Capital Partners
XMS Capital Partners, established in 2006, is a global, independent financial services firm providing investment banking, asset management and merchant banking services to clients. It has offices in Chicago, London and Dublin.
XMS provides Involvement BankingTM, which goes beyond transaction oriented investment banking and focuses on delivering objective, value added advice and custom tailored solutions to help clients achieve their strategic goals. It consistently creates value for its clients by giving them access to comprehensive, independent M&A, strategic advisory, financial restructuring, capital structure advisory and private capital advisory expertise.
XMS Capital Partners, LLC is a FINRA member and SIPC member. XMS Capital Partners (UK) Limited is authorized and regulated by the Financial Conduct Authority. For more information, please visit www.xmscapital.com.
Edwards Lifesciences, based in Irvine, Calif., is the global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring. Driven by a passion to help patients, the company collaborates with the world’s leading clinicians and researchers to address unmet healthcare needs, working to improve patient outcomes and enhance lives. For more information, visit www.edwards.com.
CASMED’s vision is: “That no patient is harmed by undetected tissue hypoxia.” The FORE-SIGHT Cerebral Oximeters provide a highly accurate, non-invasive measurement of tissue oxygenation in the brain. Direct monitoring of tissue oxygenation can provide clinicians with a superior and powerful tool to alert them to otherwise unrecognized and dangerous hypoxia, or low levels of oxygen, in the brain and other tissue, thereby empowering them to improve patient care. For more information, visit www.casmed.com.